Govt moves high-alcohol liquid medicines to Schedule H1, tightening pharmacy sales
Health ministry reclassifies oral liquids with over 12% alcohol in bottles above 30ml to restricted Schedule H1, mandating prescriptions and stricter record-keeping. Cough syrups and tonics affected; chemists and manufacturers get a six-month compliance window.
What happened
retail-company · Health ministry moved oral liquid medicines with over 12% alcohol in bottles above 30ml to restricted Schedule H1, requiring prescriptions and
Key facts
- 12% ethyl alcohol
- 30 ml
- 80-90%
- six months
- $60 billion 2026
- $130 billion 2030
Why this matters
The tighter Schedule H1 regime raises compliance barriers that could accelerate consolidation among smaller chemists and reshape supplier terms with cough syrup and tonic manufacturers.
What to watch
- Final gazette notification with exact alcohol/volume thresholds and SKU list
- Manufacturer reformulation announcements or new pack launches
- State drug-controller enforcement actions or inspection ramp-up
- Category volume data from chemist channel post-implementation
- Industry body (AIOCD/OPPI) representations seeking timeline extension
- Chemist chains audit affected SKU inventory and set return/exchange terms with distributors before window closes
- Manufacturers accelerate sub-12% reformulations and <30ml pack redesigns
- Pharmacy POS/software vendors push H1 register and prescription-logging modules
- Distributors rebalance stock away from restricted SKUs to avoid dead inventory
- Marketing pivots to promote compliant OTC alternatives and vitamin/tonic substitutes